ArQule, Inc. to Introduce Novel FGFR Inhibitor Program Discovered Through Its Proprietary Kinase Inhibitor Platform at ArQule, Inc.-American Association for Cancer Research-EORTC Conference

WOBURN, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced that a presentation at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics in Boston on November 16, 2009, will highlight the discovery of potent, small molecule inhibitors of fibroblast growth factor receptor (FGFR) through the application of its proprietary ArQule Kinase Inhibitor Platform (AKIP™).